You are here

Healthcare Economics

 

A simulation model of U.S. adults found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were not cost-effective in patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).

 

 

Recent Headlines

St. Jude Medical’s stock falls following short seller’s report on potential hacking issues

St. Jude Medical’s common stock price fell by more 5 percent on Aug. 25 after a research firm announced it had shorted the company’s stock.

Medtronic’s quarterly earnings beat analysts’ estimates

For the first quarter of fiscal year 2017, Medtronic’s revenue decreased 1 percent to $7.166 billion and its non-GAAP diluted earnings increased approximately 14 to 16 percent to $1.03 per share.

Medtronic, HeartWare complete $1.1 billion deal

Medtronic completed its acquisition of HeartWare International on Aug. 22, a deal intended to expand the company’s heart failure business.

Valeant Pharmaceuticals hires Paul Herendeen as CFO

Valeant Pharmaceuticals appointed Paul S. Herendeen as CFO and executive vice president of finance on Aug. 22.

Judge sentences New Jersey couple to six years in prison for fraudulent diagnostic testing

Two New Jersey residents were sentenced on Aug. 16 to more than six years in prison apiece for forging physician signatures and writing and interpreting fraudulent reports for diagnostic testing that were never interpreted by a licensed physician.

Financial incentives may help adults quit smoking in the long-term

Providing financial incentives to low-income smokers led to increased long-term rates of smoking cessation, according to a study in Switzerland.

Model finds PCSK9 inhibitors are not cost-effective

A simulation model of U.S. adults found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were not cost-effective in patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).

Cardiac bundles won’t hurt bottom line in majority of hospitals

The majority of hospitals required to participate in the Centers for Medicare and Medicaid Innovation cardiac bundled payment arrangement will not incure large financial gains or losses. 

Cardiovascular Systems posts net loss in fourth quarter of fiscal year 2016

For the fourth quarter of fiscal year 2016, Cardiovascular Systems posted a net loss of $4.9 million and $48.4 million in revenue, nearly identical to the same period last year.

Corindus hires J. Aaron Grantham as chief medical officer

Corindus Vascular Robotics announced August 3 that it had hired J. Aaron Grantham, MD, as its chief medical officer.

Pages